Literature DB >> 14578207

Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

You-Hai Xu1, Brian Quinn, David Witte, Gregory A Grabowski.   

Abstract

Gaucher disease is an autosomal recessively inherited disease caused by mutations at the acid beta-glucosidase (GCase) locus (GBA). To develop viable models of Gaucher disease, point mutations (pmuts), encoding N370S, V394L, D409H, or D409V were introduced into the mouse GCase (gba) locus. DNA sequencing verified each unique pmut. Mutant GCase mRNAs were near wild-type (WT) levels. GCase activities were reduced to 2 to 25% of WT in liver, lung, spleen, and cultured fibroblasts from pmut/pmut or pmut/null mice. The corresponding brain GCase activities were approximately 25% of WT. N370S homozygosity was lethal in the neonatal period. For the other pmut mice, a few storage cells appeared in the spleen at > or =7 months (D409H or D409V homozygotes) or > or =1 year (V394L homozygotes). V394L/null, D409H/null, or D409V/null mice showed scattered storage cells in spleen at approximately 3 to 4 months. Occasional storage cells (sinusoidal cells) were present in liver. In D409V/null mice, large numbers of Mac-3-positive storage cells (ie, macrophages) accumulated in the lung. Glycosphingolipid analyses showed varying rates of progressive glucosylceramide accumulation in visceral organs of pmut/pmut or pmut/null mice, but not in brain. These GCase-deficient mice provide tools for gaining insight into the pathophysiology of Gaucher disease and developing improved therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578207      PMCID: PMC1892407          DOI: 10.1016/s0002-9440(10)63566-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

Authors:  J Charrow; H C Andersson; P Kaplan; E H Kolodny; P Mistry; G Pastores; B E Rosenbloom; C R Scott; R S Wappner; N J Weinreb; A Zimran
Journal:  Arch Intern Med       Date:  2000-10-09

2.  A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice.

Authors:  C Vogler; E H Birkenmeier; W S Sly; B Levy; C Pegors; J W Kyle; W G Beamer
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

3.  Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes.

Authors:  Chi-Ming Li; Jae-Ho Park; Calogera M Simonaro; Xingxuan He; Ronald E Gordon; Adriana-Haimovitz Friedman; Desiree Ehleiter; Francois Paris; Katia Manova; Stefan Hepbildikler; Zvi Fuks; Konrad Sandhoff; Richard Kolesnick; Edward H Schuchman; Stefan Hepbiloikler
Journal:  Genomics       Date:  2002-02       Impact factor: 5.736

4.  Correction of murine mucopolysaccharidosis VII by a human beta-glucuronidase transgene.

Authors:  J W Kyle; E H Birkenmeier; B Gwynn; C Vogler; P C Hoppe; J W Hoffmann; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  Comparison of RNase A, a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene.

Authors:  B D Theophilus; T Latham; G A Grabowski; F I Smith
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

6.  Gaucher disease: molecular heterogeneity and phenotype-genotype correlations.

Authors:  B Theophilus; T Latham; G A Grabowski; F I Smith
Journal:  Am J Hum Genet       Date:  1989-08       Impact factor: 11.025

7.  Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: molecular and pathological analyses.

Authors:  L S Finn; M Zhang; S H Chen; C R Scott
Journal:  Am J Med Genet       Date:  2000-03-20

8.  Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

Authors:  D Fabbro; R J Desnick; G A Grabowski
Journal:  Am J Hum Genet       Date:  1987-01       Impact factor: 11.025

9.  Comparison of the chromosomal localization of murine and human glucocerebrosidase genes and of the deduced amino acid sequences.

Authors:  R R O'Neill; T Tokoro; C A Kozak; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene.

Authors:  N Dahl; M Lagerström; A Erikson; U Pettersson
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

View more
  79 in total

1.  Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.

Authors:  Ying Sun; Benjamin Liou; You-Hai Xu; Brian Quinn; Wujuan Zhang; Rick Hamler; Kenneth D R Setchell; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

3.  Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease.

Authors:  Manoj Kumar Pandey; Reena Rani; Wujuan Zhang; Kenneth Setchell; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2012-04-30       Impact factor: 4.797

4.  Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.

Authors:  John Marshall; Kerry Anne McEachern; Wei-Lien Chuang; Elizabeth Hutto; Craig S Siegel; James A Shayman; Greg A Grabowski; Ronald K Scheule; Diane P Copeland; Seng H Cheng
Journal:  J Inherit Metab Dis       Date:  2010-03-25       Impact factor: 4.982

5.  Gaucher disease in sheep.

Authors:  Litsa Karageorgos; Malcolm J Lancaster; Judith S Nimmo; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

Review 6.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 7.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

8.  Murine models of acute neuronopathic Gaucher disease.

Authors:  Ida Berglin Enquist; Christophe Lo Bianco; Andreas Ooka; Eva Nilsson; Jan-Eric Månsson; Mats Ehinger; Johan Richter; Roscoe O Brady; Deniz Kirik; Stefan Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

9.  Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.

Authors:  David E Sleat; Mukarram El-Banna; Istvan Sohar; Kwi-Hye Kim; Kostantin Dobrenis; Steven U Walkley; Peter Lobel
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

10.  Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

Authors:  You-Hai Xu; Rachel Reboulet; Brian Quinn; Joerg Huelsken; David Witte; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.